Now recruiting male participants for a Phase III clinical trial for androgenic alopecia
The Triple Hair team is actively recruiting men experiencing hair loss to participate in a Phase III clinical trial with our innovative topical solution, TH07.
Revolutionary hair growth therapies
Triple Hair is a clinical-stage Canadian biotechnology company specialized in the development of innovative treatments for alopecia.
Therapy-07
Prescription
This triple combination therapy works synergistically to encourage optimal hair regrowth in men with androgenic alopecia. Significant regrowth was observed among participants in the clinical trials.
Therapy-16
Over-the-counter natural product
This clinically proven, natural combination formula beats market-leading, synthetic formulas and is the perfect choice for men and women looking to prevent hair loss and boost hair growth, thickness, and pigmentation.
Our
philosophy
Triple Hair was founded on a deeply personal conviction: that people suffering from hair loss deserve real, science-backed solutions. Inspired by Dr. Houfar Sekhavat’s own experience, we are committed to developing safe and effective therapies while fostering open collaboration with the global scientific community. The potential to improve millions of lives is not just our motivation, it is our responsibility.
Looking
to invest?
While Triple Hair is well positioned financially, we welcome conversations with investors who share our vision for advancing hair loss research. If you’re interested in supporting the next stage of clinical development, we’d be happy to connect and share more about our current or upcoming financing opportunities.
Our executive
team
Behind every Triple Hair therapy is a team of dedicated scientists, clinicians, and innovators who refuse to settle for incremental progress. Together, they have built a pipeline of clinically validated treatments that are redefining what’s possible in hair loss care.
The hair loss
market in 2025
20%
20% of the world's population suffers from hair loss (alopecia).
$8.77 B
Hair loss treatments are a US$8.77 billion industry.
80 M
80 million people suffer from hair loss in the United States alone.
studies
Triple Hair is now recruiting male patients for Phase III clinical trials for TH07, our triple combination therapy for androgenic alopecia, across multiple sites in Canada and India. The trial is a triple-blind, randomized, placebo-controlled study running over the course of one year. This milestone study brings us one step closer to making TH07 widely available to the millions of men affected by hair loss.
Recent publications
Corporate and scientific news
Subscribe to our mailing list